234 related articles for article (PubMed ID: 23149842)
21. Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer.
Hebbring SJ; Fredriksson H; White KA; Maier C; Ewing C; McDonnell SK; Jacobsen SJ; Cerhan J; Schaid DJ; Ikonen T; Autio V; Tammela TL; Herkommer K; Paiss T; Vogel W; Gielzak M; Sauvageot J; Schleutker J; Cooney KA; Isaacs W; Thibodeau SN
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):935-8. PubMed ID: 16702373
[TBL] [Abstract][Full Text] [Related]
22. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
23. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
[TBL] [Abstract][Full Text] [Related]
24. BARD1 and breast cancer in Poland.
Jakubowska A; Cybulski C; Szymańska A; Huzarski T; Byrski T; Gronwald J; Debniak T; Górski B; Kowalska E; Narod SA; Lubiński J
Breast Cancer Res Treat; 2008 Jan; 107(1):119-22. PubMed ID: 17333333
[TBL] [Abstract][Full Text] [Related]
25. The risk of gastric cancer in carriers of CHEK2 mutations.
Teodorczyk U; Cybulski C; Wokołorczyk D; Jakubowska A; Starzyńska T; Lawniczak M; Domagała P; Ferenc K; Marlicz K; Banaszkiewicz Z; Wiśniowski R; Narod SA; Lubiński J
Fam Cancer; 2013 Sep; 12(3):473-8. PubMed ID: 23296741
[TBL] [Abstract][Full Text] [Related]
26. CHEK2 mutations and the risk of papillary thyroid cancer.
Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S
Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358
[TBL] [Abstract][Full Text] [Related]
27. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.
Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; Gliniewicz B; Sikorski A; Stawicka M; Godlewski D; Kwias Z; Antczak A; Krajka K; Lauer W; Sosnowski M; Sikorska-Radek P; Bar K; Klijer R; Zdrojowy R; Małkiewicz B; Borkowski A; Borkowski T; Szwiec M; Narod SA; Lubiński J
J Med Genet; 2006 Nov; 43(11):863-6. PubMed ID: 17085682
[TBL] [Abstract][Full Text] [Related]
28. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.
Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; van de Wetering T; Narod SA; Lubiński J
Breast Cancer Res Treat; 2007 Mar; 102(1):119-22. PubMed ID: 16897426
[TBL] [Abstract][Full Text] [Related]
29. Breast cancer susceptibility genes.
Lubinski J; Korzen M; Gorski B; Cybulski C; Debniak T; Jakubowska A; Medrek K; Matyjasik J; Huzarski T; Byrski T; Gronwald J; Masojc B; Lener M; Szymanska A; Szymanska-Pasternak J; Fernandez PS; Wokolorczyk D; Piegat A; Ucinski M; Domagala P; Kladny J; Gorecka B; Scott R; Narod S
J BUON; 2007 Sep; 12 Suppl 1():S23-9. PubMed ID: 17935274
[TBL] [Abstract][Full Text] [Related]
30. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
[TBL] [Abstract][Full Text] [Related]
31. Survival of bladder or renal cancer in patients with CHEK2 mutations.
Złowocka-Perłowska E; Dębniak T; Słojewski M; van de Wetering T; Tołoczko-Grabarek A; Cybulski C; Scott RJ; Lubiński J
PLoS One; 2021; 16(9):e0257132. PubMed ID: 34499690
[TBL] [Abstract][Full Text] [Related]
32. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
33. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
[TBL] [Abstract][Full Text] [Related]
34. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
[TBL] [Abstract][Full Text] [Related]
35. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
[TBL] [Abstract][Full Text] [Related]
36. BRCA1 mutations and colorectal cancer in Poland.
Suchy J; Cybulski C; Górski B; Huzarski T; Byrski T; Dębniak T; Gronwald J; Jakubowska A; Wokołorczyk D; Kurzawski G; Kładny J; Jawień A; Banaszkiewicz Z; Wiśniowski R; Wandzel P; Starzewski J; Lorenc Z; Korobowicz E; Krokowicz P; Horbacka K; Lubiński J; Narod SA
Fam Cancer; 2010 Dec; 9(4):541-4. PubMed ID: 20862552
[TBL] [Abstract][Full Text] [Related]
37. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
[TBL] [Abstract][Full Text] [Related]
38. Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers.
Rebbeck TR; Mitra N; Domchek SM; Wan F; Chuai S; Friebel TM; Panossian S; Spurdle A; Chenevix-Trench G; ; Singer CF; Pfeiler G; Neuhausen SL; Lynch HT; Garber JE; Weitzel JN; Isaacs C; Couch F; Narod SA; Rubinstein WS; Tomlinson GE; Ganz PA; Olopade OI; Tung N; Blum JL; Greenberg R; Nathanson KL; Daly MB
Cancer Res; 2009 Jul; 69(14):5801-10. PubMed ID: 19584272
[TBL] [Abstract][Full Text] [Related]
39. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland.
Steffen J; Nowakowska D; Niwińska A; Czapczak D; Kluska A; Piatkowska M; Wiśniewska A; Paszko Z
Int J Cancer; 2006 Jul; 119(2):472-5. PubMed ID: 16770759
[TBL] [Abstract][Full Text] [Related]
40. NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia.
Buslov KG; Iyevleva AG; Chekmariova EV; Suspitsin EN; Togo AV; Kuligina ESh; Sokolenko AP; Matsko DE; Turkevich EA; Lazareva YR; Chagunava OL; Bit-Sava EM; Semiglazov VF; Devilee P; Cornelisse C; Hanson KP; Imyanitov EN
Int J Cancer; 2005 Apr; 114(4):585-9. PubMed ID: 15578693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
